Effect of histone deacetylase and its inhibitor on tumor

doi:10.3760/cma.j.issn.1673-422X.2019.04.009

Abstract

Abstract: The occurrence and progress of tumor is the result of the interaction of heredity and epigenetics. Histone deacetylation modification, as an important epigenetic modification, plays an important role in tumorigenesis and development. The abnormal expression of histone deacetylase in normal tissues and cells promotes the development of tumor and is related to the proliferation and apoptosis, angiogenesis, metastasis and drug resistance of tumor cells, and becomes a new target of tumor therapy. Histone deacetylase inhibitors as antitumor drugs have a good prospect of application.

Key words: Histone deacetylases, Neoplasm metastasis, Antineoplastic agents, Histone deacetylase inhibitors

Liang Jing1,3, Han Sha2, Yao Jing3, Kong Qingsheng2. Effect of histone deacetylase and its inhibitor on tumor[J]. Journal of International Oncology, 2019, 46(4): 235-238.

References

［1］ Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492. ［2］ La Noce M, Paino F, Mele L, et al. HDAC2 depletion promotes osteosarcoma′s stemness both in vitro and in vivo: a study on a putative new target for CSCs directed therapy［J］. J Exp Clin Cancer Res, 2018, 37(1): 296. DOI: 10.1186/s13046-018-0978-x. ［3］ Deng R, Zhang P, Liu W, et al. HDAC is indispensable for IFN-gamma-induced B7-H1 expression in gastric cancer［J］. Clin Epigenetics, 2018, 10(1): 153. DOI: 10.1186/s13148-018-0589-6. ［4］ Kang ZH, Wang CY, Zhang WL, et al. Histone deacetylase HDAC4 promotes gastric cancer SGC-7901 cells progression via p21 repression［J］. PLoS One, 2014, 9(6): e98894. DOI: 10.1371/journal.pone.0098894. ［5］ Dong J, Zheng N, Wang X, et al. A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer［J］. Eur J Pharmacol, 2018, 828: 67-79. DOI: 10.1016/j.ejphar.2018.03.026. ［6］ Ahn MY, Yoon JH. Histone deacetylase 7 silencing induces apoptosis and autophagy in salivary mucoepidermoid carcinoma cells［J］. J Oral Pathol Med, 2017, 46(4): 276-283. DOI: 10.1111/jop.12560. ［7］ Hung KC, Lin ML, Hsu SW, et al. Suppression of Akt-mediated HDAC3 expression and CDK2 T39 phosphorylation by a bichalcone analog contributes to S phase retardation of cancer cells［J］. Eur J Pharmacol, 2018, 829: 141-150. DOI: 10.1016/j.ejphar.2018.04.017. ［8］ Zhang H, Liu L, Liu C, et al. Notch3 overexpression enhances progression and chemoresistance of urothelial carcinoma［J］. Oncotarget, 2017, 8(21): 34362-34373. DOI: 10.18632/oncotarget.16156. ［9］ Pinazza M, Ghisi M, Minuzzo S, et al. Histone deacetylase 6 controls Notch3 trafficking and degradation in T-cell acute lymphoblastic leukemia cells［J］. Oncogene, 2018, 37(28): 3839-3851. DOI: 10.1038/s41388-018-0234-z. ［10］ Terranova-Barberio M, Thomas S, Ali N, et al. HDAC inhibition potentiates immunotherapy in triple negative breast cancer［J］. Oncotarget, 2017, 8(69): 114156-114172. DOI: 10.18632/oncotarget.23169. ［11］ Bian X, Liang Z, Feng A, et al. HDAC inhibitor suppresses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL［J］. Biochem Pharmacol, 2018, 147: 30-37. DOI: 10.1016/j.bcp.2017.11.008. ［12］ Peng Z, Zhou W, Zhang C, et al. Curcumol controls choriocarcinoma stem-like cells self-renewal via repression of DNA methyltransferase (DNMT)- and histone deacetylase (HDAC)-mediated epigenetic regulation［J］. Med Sci Monit, 2018, 24: 461-472. ［13］ Gatla HR, Zou Y, Uddin MM, et al. Histone deacetylase (HDAC) inhibition induces IkappaB kinase (IKK)-dependent interleukin-8/CXCL8 expression in ovarian cancer cells［J］. J Biol Chem, 2017, 292(12): 5043-5054. DOI: 10.1074/jbc.M116.771014. ［14］ Kowshik J, Giri H, Kishore TK, et al. Ellagic acid inhibits VEGF/VEGFR2, PI3K/Akt and MAPK signaling cascades in the hamster cheek pouch carcinogenesis model［J］. Anticancer Agents Med Chem, 2014, 14(9): 1249-1260. ［15］ Huang YC, Huang FI, Mehndiratta S, et al. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis［J］. Oncotarget, 2015, 6(21): 18590-18601. DOI: 10.18632/oncotarget.4068. ［16］ Yao ZG, Li WH, Hua F, et al. LBH589 inhibits glioblastoma growth and angiogenesis through suppression of HIF-1alpha expression［J］. J Neuropathol Exp Neurol, 2017, 76(12): 1000-1007. DOI: 10.1093/jnen/nlx088. ［17］ Campbell S, Suwan K, Waramit S, et al. Selective inhibition of histone deacetylation in melanoma increases targeted gene delivery by a bacteriophage viral vector［J］. Cancers (Basel), 2018, 10(4). pii: cancers10040125. DOI: 10.3390/cancers10040125. ［18］ Tao H, Chen YY, Sun ZW, et al. Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90［J］. J Cell Biochem, 2018, 119(8): 6623-6632. DOI: 10.1002/jcb.26841. ［19］ Wu YW, Hsu KC, Lee HY, et al. A novel dual HDAC6 and tubulin inhibitor, MPT0B451, displays anti-tumor ability in human cancer cells in vitro and in vivo［J］. Front Pharmacol, 2018, 9: 205. DOI: 10.3389/fphar.2018.00205. ［20］ Shen YF, Wei AM, Kou Q, et al. Histone deacetylase 4 increases progressive epithelial ovarian cancer cells via repression of p21 on fibrillar collagen matrices［J］. Oncol Rep, 2016, 35(2): 948-954. DOI: 10.3892/or.2015.4423. ［21］ Chen X, Li D, Gao Y, et al. Histone deacetylase SIRT6 inhibits glioma cell growth through down-regulating NOTCH3 expression［J］. Acta Biochim Biophys Sin (Shanghai), 2018, 50(4): 417-424. DOI: 10.1093/abbs/gmy019. ［22］ Liu C, Lv D, Li M, et al. Hypermethylation of miRNA-589 promoter leads to upregulation of HDAC5 which promotes malignancy in non-small cell lung cancer［J］. Int J Oncol, 2017, 50(6): 2079-2090. DOI: 10.3892/ijo.2017.3967. ［23］ Hegedus L, Padanyi R, Molnar J, et al. Histone deacetylase inhibitor treatment increases the expression of the plasma membrane Ca2+ pump PMCA4b and inhibits the migration of melanoma cells independent of ERK［J］. Front Oncol, 2017, 7: 95. DOI: 10.3389/fonc.2017.00095. ［24］ McLeod AB, Stice JP, Wardell SE, et al. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer［J］. Prostate, 2018, 78(4): 266-277. DOI: 10.1002/pros.23467. ［25］ Luo S, Ma K, Zhu H, et al. Molecular, biological characterization and drug sensitivity of chidamide-resistant non-small cell lung cancer cells［J］. Oncol Lett, 2017, 14(6): 6869-6875. DOI: 10.3892/ol.2017.7060. ［26］ Wang Y, Jin T, Dai X, et al. Histone deacetylase enzyme silencing using shRNAs enhances radiosensitivity of SW579 thyroid cancer cells［J］. Mol Med Rep, 2016, 14(4): 3509-3516. DOI: 10.3892/mmr.2016.5711. ［27］ Yoon S, Eom GH. HDAC and HDAC inhibitor: from cancer to cardiovascular diseases［J］. Chonnam Med J, 2016, 52(1): 1-11. DOI: 10.4068/cmj.2016.52.1.1. ［28］ Bae J, Hideshima T, Tai YT, et al. Histone deacetylase (HDAC) inhibitor ACY241 enhances antitumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors［J］. Leukemia, 2018, 32(9): 1932-1947. DOI: 10.1038/s41375-018-0062-8. ［29］ Su Y, Hopfinger NR, Nguyen TD, et al. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors［J］. J Exp Clin Cancer Res, 2018, 37(1): 314. DOI: 10.1186/s13046-018-0988-8. ［30］ Carbone C, Di Gennaro E, Piro G, et al. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat［J］. Amino Acids, 2017, 49(3): 517-528. DOI: 10.1007/s00726-016-2338-5.

[1]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[2]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[3]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying. Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2023, 50(8): 475-483.
[6]	Yang Lirong, Wang Yufeng. Construction of machine learning models for predicting the risk of postoperative distant metastasis recurrence in serous ovarian cancer [J]. Journal of International Oncology, 2023, 50(4): 220-226.
[7]	Ma Peihan, Zhang Lingming, Lu Ning, Zhang Mingxin. Effect of anesthesia on the recurrence and metastasis of hepatocellular carcinoma [J]. Journal of International Oncology, 2023, 50(2): 117-121.
[8]	Zhao Jianhao, Duan Yanchao. Research progress in the pathogenesis of extramedullary disease in multiple myeloma [J]. Journal of International Oncology, 2023, 50(1): 55-59.
[9]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou. Advances in immunotherapy for recurrent and metastatic cervical cancer [J]. Journal of International Oncology, 2022, 49(9): 517-520.
[10]	Peng Chen, Xie Yintong, Zhang Xin, Xie Peng. Research progress of maintenance therapy for cervical cancer [J]. Journal of International Oncology, 2022, 49(7): 430-435.
[11]	Wang Liwei, Liang Hongsheng, Du Songlin, Chen Zhihao, Wang Qing, Gao Aili. Research progress of avermectins in anti-tumor [J]. Journal of International Oncology, 2022, 49(6): 353-356.
[12]	Wang Bin, Zhou Jiangyun, Liu Xi. Analysis of the clinical value of different radiotherapy schemes in patients with advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2021, 48(8): 484-488.
[13]	Chi Xiuying, Wang Hongbiao, Li Zhifeng, Lin Yingcheng. Progression in the therapies of relapse or metastatic esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2021, 48(12): 755-759.
[14]	Dai Ang, Sun Qing. CRYAB and tumors [J]. Journal of International Oncology, 2020, 47(6): 351-354.
[15]	Yang Chao, Wang Jianbo, Zhang Juhong, Wang Jialong. Overexpression of miR-125 inhibits proliferation and invasion of nasopharyngeal carcinoma cells by down-regulating FGF-2 [J]. Journal of International Oncology, 2020, 47(5): 257-263.